ASC30 is an experimental daily GLP-1 pill with encouraging early diabetes results. The findings support further study, but they don't establish that it works better than today's medicines. GLP-1 is a gut-hormone signal involved in blood sugar and fullness.
As of October 29, 2026, the day this article was written, Ascletis's October 28 announcement reports improved blood sugar and weight versus placebo. The release was issued at 19:40 ET. These are the company's initial results, before a peer-reviewed diabetes paper checked by outside experts.
What the ASC30 diabetes trial found
The ClinicalTrials.gov record, updated September 21, 2026, lists 100 participants and a completed study. It describes random assignment to three ASC30 groups or placebo, a look-alike tablet without active medicine. Participants and the teams caring for and assessing them were kept unaware of assignments.
Eligible adults were 18–75, had type 2 diabetes and had stable weight. Their HbA1c, a blood test reflecting average blood sugar over roughly three months, had to be 7.0%–10.5%. People with type 1 diabetes or certain uncontrolled illnesses were excluded.
Ascletis reported these differences after subtracting the placebo group's change:
| Daily trial dose | HbA1c reduction at 12 weeks | Weight reduction at 13 weeks |
|---|---|---|
| 40 mg | 1.7 percentage points | 4.4% |
| 60 mg | 1.6 percentage points | 3.8% |
| 80 mg | 1.7 percentage points | 4.0% |
For 40 mg, the release's “1.7%” blood-sugar figure means percentage points. Its “4.4%” weight figure refers to starting body weight. These are different kinds of percentages.
The analysis estimated results if eligible participants stayed on treatment. That doesn't necessarily describe what happens when people stop. The trial increased doses weekly from 1 mg; those are study facts, not a prescribing schedule.
What this means for someone considering semaglutide
For someone already discussing treatment, the immediate change is a new candidate to follow. ASC30 is not FDA-approved; it remains an investigational medicine. This announcement doesn't create a new routine prescription option.
Semaglutide already has published diabetes studies. PIONEER 1, in Diabetes Care in 2019, tested a manufacturer-made oral formulation in 703 adults over 26 weeks. That is a different medicine, formulation and study length.
Through Promise, semaglutide is dispensed by a licensed U.S. compounding pharmacy as a compounded medication. This is different from an FDA-approved product: the formulation offered here is not FDA-approved. The ASC30 findings don't establish outcomes for that preparation.
Why a small molecule matters
ASC30 is a small molecule: a compact chemical rather than a peptide, a chain of amino acids. It activates the GLP-1 receptor, the cell switch receiving that hormone signal.
Peptide pills are harder to make because digestion breaks peptides down and little crosses into the blood. Buckley and colleagues' 2018 Science Translational Medicine study explains how semaglutide uses an added ingredient to protect it and help it cross the stomach lining. The oral semaglutide guide explains that delivery system.
Another small-molecule pill, orforglipron, sold as Foundayo, is already approved in the U.S. Its FDA label, revised July 2026, covers adult weight management, rather than diabetes treatment. The Foundayo label guide explains those uses.
Where tirzepatide fits today
Tirzepatide adds a second hormone pathway, GIP, another gut signal involved in blood-sugar control. That makes it a different molecule again.
SURPASS-2, published in the New England Journal of Medicine in 2021, compared manufacturer-made tirzepatide with injectable semaglutide. It followed 1,879 adults with type 2 diabetes over 40 weeks. It didn't test ASC30. Its direct comparison answers a different question from this new placebo-controlled trial.
Through Promise, tirzepatide is dispensed by a licensed U.S. compounding pharmacy as a compounded medication. This is different from an FDA-approved product: the formulation offered here is not FDA-approved. Neither trial establishes results for that compounded preparation. A licensed provider may still prescribe — that decision is between you and your doctor.
What the side-effect headlines leave open
The announcement reports “zero study discontinuations due to GI adverse events (AEs)” — digestive side effects. That means nobody left the study for those problems. It doesn't mean nobody felt sick. The release doesn't provide nausea or vomiting rates by dose.
It reports one withdrawal for hiccups, written as 1/80, or 1.3%, and none for any side effect with placebo. Drug-related side effects were described as mild or moderate, with none classified as serious.
The release also states: “No hepatic safety signal was observed.” Hepatic means liver-related. It reports no rises in the liver blood tests it names during treatment.
Those are reassuring observations within a short study. They cannot rule out uncommon problems or show what happens after years of use. A study can have no withdrawals for a symptom and still have symptoms worth discussing.
What the results cannot settle
This was a small diabetes study, not a direct contest against semaglutide, tirzepatide or Foundayo. Different starting blood-sugar levels, study lengths and ways of counting participants can change the numbers. Putting percentages side by side doesn't remove those differences.
Two reporting details also need explanation in a full paper. The registry lists the main blood-sugar measurement at week 13; the announcement reports week 12. Its treatment-group counts total 77 for the results, while its withdrawal calculation uses 80. The release doesn't explain the week difference; its efficacy-estimand footnote, which counts “randomized eligible participants while adhering to treatment,” may account for the smaller count, but it doesn't say so.
That doesn't erase the findings. It does mean the complete methods matter before drawing a firm comparison.
What to watch next
The useful next step is a full diabetes publication with the methods, participant accounting and side-effect rates. Longer studies also need to show how many people keep taking ASC30 and how their blood sugar changes over time.
Ascletis describes later-stage obesity studies as underway. Obesity results and diabetes results answer related questions, but one cannot stand in for the other. A development plan also isn't a date when a prescription becomes available.
For someone considering semaglutide now, ASC30's news adds a future possibility. Today's discussion still rests on the person's health history and evidence for the medicine and preparation actually being considered.
The prescription decision today
A news result doesn't determine an individual treatment plan. At Promise, a licensed provider reviews every request, and not everyone qualifies. The review considers medical history, current medicines and treatment goals. The prescriber sets the actual dose when a prescription is appropriate, and a licensed U.S. compounding pharmacy prepares and dispenses the compounded medication.
